Watch NEO. Know when insiders buy.
One email the day a filing lands. Free.
NEO
NEOGENOMICS INC
16.69
+0.10 +0.60%
USD · close Oct 26
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
52
WATCH · shorts 52
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
1 / 0
buys / sells · latest disclosed Sep 10
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.1BP/E —DIV YIELD —FCF YIELD -0.34%REV TTM —NET INCOME −$51.9MNET DEBT $196.3M52W 7.19 – 19.91SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$9.8M | $2.2M | — | — | $20M | $8.2M | $11.7M | Jul 28 |
| Q1 2026 · Mar 31 | — | — | — | −$18.2M | −$17.1M | — | — | −$8.1M | $5M | −$13.1M | Jul 28 |
| Q4 2025 · Dec 31derived | — | — | — | −$13.4M | −$9.9M | — | — | $1.3M | $7.9M | −$6.5M | Feb 17 |
| Q3 2025 · Sep 30 | — | — | — | −$27M | −$27.1M | — | — | $8.9M | $8.3M | $570K | Oct 28 |
| Q2 2025 · Jun 30 | — | — | — | −$47.6M | −$45.1M | — | — | $20.3M | $6.3M | $14M | Jul 28 |
| Q1 2025 · Mar 31 | — | — | — | −$27.8M | −$25.9M | — | — | −$25.3M | $4.5M | −$29.8M | Jul 28 |
| Q4 2024 · Dec 31derived | — | — | — | −$18.4M | −$15.3M | — | — | $9.8M | $11.6M | −$1.8M | Feb 17 |
| Q3 2024 · Sep 30 | — | — | — | −$21.2M | −$17.7M | — | — | $9.2M | $10.8M | −$1.6M | Oct 28 |
| Q2 2024 · Jun 30 | — | — | — | −$21.9M | −$18.6M | — | — | $13.9M | $13.1M | $814K | Oct 28 |
| Q1 2024 · Mar 31 | — | — | — | −$30.6M | −$27.1M | — | — | −$25.9M | $5.6M | −$31.5M | Oct 28 |
| Q4 2023 · Dec 31derived | — | — | — | −$18.6M | −$14.3M | — | — | $17.8M | $7.1M | $10.7M | Feb 17 |
| Q3 2023 · Sep 30 | — | — | — | −$24.2M | −$18.5M | — | — | −$5.5M | $4.3M | −$9.8M | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$115.9M | −$108M | — | — | $5.2M | $27M | −$21.8M | — | — |
| FY2024 · to Dec 31 | — | — | −$92.1M | −$78.7M | — | — | $7M | $41.1M | −$34M | — | — |
| FY2023 · to Dec 31 | — | — | −$107.7M | −$88M | — | — | −$2M | $28.8M | −$30.7M | — | — |
| FY2022 · to Dec 31 | — | — | −$157.6M | −$144.3M | — | — | −$66M | $30.9M | −$96.9M | — | — |
| FY2021 · to Dec 31 | — | — | −$118.8M | −$8.3M | — | — | −$26.7M | $64.1M | −$90.9M | — | — |
| FY2020 · to Dec 31 | — | — | −$14M | $4.2M | — | — | $1.5M | $29.1M | −$27.6M | — | — |
Every number comes from NEOGENOMICS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.